Lv1
38 积分 2026-03-17 加入
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
1个月前
已完结
Bias, Operational Bias, and Generalizability in Phase II/III Trials
1个月前
已完结
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial
1个月前
已完结
Design issues in randomized phase II/III trials
1个月前
已完结
DIA’s Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for “Less Well-understood” Adaptive Designs
1个月前
已完结
A Comparison of Methods for Treatment Selection in Seamless Phase II/III Design
1个月前
已完结
Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study
1个月前
已完结
Assessing the performance of methods for central statistical monitoring of a binary or continuous outcome in multi-center trials: A simulation study
2个月前
已完结
Evaluation of current statistical methods for implementing Quality Tolerance Limits
2个月前
已完结
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer
2个月前
已完结
皖公网安备34019202002308
